Skip to main content

Table 4 Change from Baseline in CGI-BP-S-depression and CGI-BP-S-overall

From: Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

PLO NA −0.25 [− 0.38,-0.11] −0.59 [− 2.06, 0.76] −0.55 [− 0.68–0.41] −0.05 [− 0.26, 0.17] −0.63 [− 0.87,-0.39]
−0.21 [− 0.63, 0.20] ARI NA NA NA NA NA
NA NA CAR −0.34 [− 1.82, 1.01] −0.30 [− 0.49,-0.11] 0.20 [− 0.05, 0.46] −0.38 [− 0.66,-0.10]
−0.32 [− 0.72, 0.08] −0.11 [− 0.68, 0.47] NA OLA 0.04 [− 1.31, 1.51] 0.54 [− 0.83, 2.03] −0.04 [− 1.41, 1.46]
NA NA NA NA QUE 0.50 [0.24, 0.76] −0.08 [− 0.36, 0.19]
NA NA NA NA NA ZIP −0.58 [− 0.91,-0.26]
− 0.63 [− 1.12,-0.14] −0.42 [− 1.06, 0.23] NA − 0.31 [− 0.95, 0.33] NA NA LUR
  1. Note: CGI-BP-S-overall are on the top-right and CGI-BP-S-depression results are on the bottom-left. Numbers represent the mean change [95% credible interval]. In the top-right comparisons, the row treatment is the reference category. In the bottom-left, the column treatment is the reference category
  2. Abbreviations: CGI-BP-S Clinical Global Impressions–Bipolar–Severity Scale, PLO Placebo, ARI Aripiprazole, CAR Cariprazine, LUR Lurasidone, OLA Olanzapine, QUE Quetiapine, ZIP Ziprasidone